Interest in the use of radionuclides for treatment of various diseases has a long history and
parallels the isolation of radium by Marie and Pierre Curie in the early part of the 20th …

Peptide receptor radionuclide therapy (PRRT) is a site-directed targeted therapeutic strategy
that specifically uses radiolabeled peptides as biological targeting vectors designed to …

Abstract “Radiotheranostics” is a term used in nuclear medicine to refer to the use of
radioisotope (RI)-labeled agents to perform simultaneous imaging and therapy of a target …

Abstract Lutetium-177 [T½= 6.76 d; E β (max)= 0.497 MeV; maximum tissue range~ 2.5 mm;
208 keV γ-ray] is one of the most important theranostic radioisotope used for the …

Background: Radioiodine therapy (131I) forms a principal cornerstone in the management of
differentiated thyroid cancer. Radioiodine-refractory differentiated thyroid cancer (RAIR …

Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC), though uncommon,
presents a considerable therapeutic challenge with poor long-term outcomes. Currently …

This paper describes the evaluation of [(R)-2-Amino-3-(4-isothiocyanatophenyl) propyl]-
trans-(S, S)-cyclohexane-1, 2-diamine-pentaacetic acid (CHX-A''-DTPA-NCS) and 2-S-(4 …

Abstract Lanthanum-132/135 is an emerging theranostic pair of radiometals that might find
widespread application in nuclear medicine. The present study describes the production of …

Introduction Integrin α v β 3 plays an important role in angiogenesis and is over-expressed
in tumoral endothelial cells and some other tumor cells. RGD (Arg-Gly-Asn) peptides labeled …

This paper explores the utility of para isothiocyanato benzyl 3, 6, 9, 15-tetraazabicyclo [9.3.
1] pentadeca-1 (15), 11, 13-triene-3, 6, 9-triacetic acid (PCTA-NCS) as a bifunctional …